Testing enzalutamide with or without mifepristone for AR-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests if adding the drug mifepristone to the standard antiandrogen enzalutamide works better than enzalutamide alone or chemotherapy for people with a specific type of breast cancer that has androgen receptors. It aims to find a new targeted treatment option for triple-negative or ER-low breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your breast cancer must be triple-negative (ER, PR, HER2 all negative) or ER-low (ER 1-10%, PR 1-10%, and HER2 negative) and has spread to other parts of the body or cannot be removed with surgery.
- Your cancer must test positive for androgen receptors (AR) — at least 10% of cancer cells show AR.
- You may have had up to 2 prior chemotherapy treatments for metastatic breast cancer, but you cannot have taken any antiandrogen therapy before.
- You cannot have a history of seizures, brain metastases, or certain heart rhythm problems (QTcF > 480 msec).
- You must be willing to undergo a research biopsy of your tumor at the start of the study (unless medically not possible).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two oral drugs—bicalutamide and abemaciclib—for people with a specific type of advanced triple-negative breast cancer that grows in response to androgen hormones (AR-positive). The goal is to see if this treatment can shrink tumors or slow disease progression.
This trial tests a new combination of two medicines for advanced prostate cancer that has spread and is no longer responding to current hormone therapy. The goal is to see if adding the experimental drug mevrometostat to enzalutamide helps control the cancer better.
This trial tests a new experimental drug (TYK-00540) combined with enzalutamide, an approved hormone therapy, for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the combination can slow cancer growth better than current options.
This trial tests whether adding specific antibiotics (amoxicillin, metronidazole, vancomycin, ciprofloxacin) to enzalutamide can help treat advanced prostate cancer that has stopped responding to other treatments. It aims to see if changing gut bacteria can make the cancer therapy work better.
This trial tests a new drug called INR731, given by mouth, for men with prostate cancer that has spread to other parts of the body. The study will check if the drug is safe and how well it works, either alone or combined with other prostate cancer medicines.
This early-phase trial tests a new treatment plan for people with metastatic triple-negative breast cancer that has already been treated with standard chemotherapy. It aims to see how well the combination works and whether it’s safe.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.